Rise and shine, everyone, the middle of the week is here. You made it this far, so why not forge ahead, yes? As always, we are doing our best with the help of some cups of stimulation — we are quaffing hazelnut this morning — and invite you to join us. After all, a prescription is not required, so go ahead and indulge. Meanwhile, we have assembled the latest menu of tidbits to get you started on another busy day. Hope all goes well and you have a productive day. Cheers …

Food and Drug Administration Commissioner Scott Gottlieb tweeted that about 400 staffers have returned to their posts from furlough, including some food inspectors and support professionals, Reuters writes. The employees returning to work, mostly without pay, include about 100 staff focused on inspections of high-risk medical device manufacturing facilities, about 70 focused on inspections of high-risk drug manufacturing facilities, and about 90 focused on inspections of high-risk biological manufacturing facilities.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy